ONCOTHERAPY SOLUTIONS, LLC

Biotech · Private

LHRH-targeted drug conjugates carrying tubulin-destabilizing agents for triple-negative breast cancer therapy

Grants
$300K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Novel peptide drug conjugates for the treatment of triple-negative breast cancers: Direct anti-tumor activity and immuno-oncology preclinical studies.$300,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1917NGM Bio Holdings, Inc.—$73M
1918CELESTIAL THERAPEUTICS INC—$125K
1919CAMBRIDGE TECHNOLOGIES LLC—$3.5M
1920ONCOTHERAPY SOLUTIONS, LLC——
1921WILD MICROBES CO——
1922Onramp Invest, Inc.—$5.0M
1923Immunocore——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.